Skip to main content
Signal8
Launch Terminal

Faeth Therapeutics, Inc. (FTH)

Faeth Therapeutics, Inc. is a clinical-stage biotechnology company focused on improving outcomes for cancer patients through multi-node inhibition of critical oncogenic pathways. [28, 70] The company's lead program, PIKTOR, is an investigational all-oral combination therapy targeting the PI3K/AKT/mTOR pathway. [28, 70]

Sector: Pharmaceutical Preparations

Industry: Biotechnology

Faeth Therapeutics, Inc. logo

Faeth Therapeutics, Inc.

NASDAQ:FTHHealthcare
-15.02%$17.08
AH Close$17.08+0.00%vs close
Mkt Cap$441.35M
Float13.98M
O/S25.84M
Inst Own54.5%
SI14.8%
Dilution
Faeth Therapeutics, Inc. logoNASDAQ:FTH$17.08-15.02%
FormDescription
8-K
5.02
4
Statement of Changes in Beneficial Ownership
3
Initial Statement of Beneficial Ownership
13G/A
Beneficial Ownership Report (Amended)
13G/A
Beneficial Ownership Report (Amended)
13G
Beneficial Ownership Report
13G/A
Beneficial Ownership Report (Amended)
144
Notice of Proposed Sale of Securities
10-Q
Quarterly Report
3
8-K
2.02,9.01
2
3
Initial Statement of Beneficial Ownership
8-K
5.02
2
4
Statement of Changes in Beneficial Ownership
4
Statement of Changes in Beneficial Ownership
4
Statement of Changes in Beneficial Ownership
4
Statement of Changes in Beneficial Ownership
4
Statement of Changes in Beneficial Ownership
4
Statement of Changes in Beneficial Ownership
3
Initial Statement of Beneficial Ownership
13G
Beneficial Ownership Report
13G
Beneficial Ownership Report
8-K
1.01,8.01,9.01
2
S-3ASR
SEC Filing
5
4
Statement of Changes in Beneficial Ownership
4
Statement of Changes in Beneficial Ownership

1-25 of 445

…